Keros Therapeutics (KROS) Common Equity (2019 - 2026)
Keros Therapeutics' (KROS) quarterly Common Equity came in at $303.1 million in Q4 2025, down 46.96% YoY from $571.6 million in Q4 2024, and down 56.92% on a QoQ basis from $703.6 million in Q3 2025.
Keros Therapeutics (KROS) Common Equity (2019 - 2026) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Common Equity data on file, last reported at $303.1 million in Q4 2025.
- Quarterly Common Equity fell 46.96% year-over-year to $303.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $303.1 million (down 46.96% YoY) and the FY2025 annual result came in at $303.1 million, down 46.96% from the prior year.
- Common Equity declined to $303.1 million in Q4 2025, from $703.6 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $728.9 million in Q1 2025 to a low of $211.2 million in Q2 2022.
- A 5-year average of $381.5 million and a median of $314.7 million in 2023 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2021 — Common Equity surged 1098.8% — and 2025, when it tumbled 46.96%.
- Tracing KROS's Common Equity over 5 years: stood at $243.2 million in 2021, then increased by 14.08% to $277.4 million in 2022, then advanced by 19.75% to $332.2 million in 2023, then jumped by 72.04% to $571.6 million in 2024, then slumped by 46.96% to $303.1 million in 2025.
- The last three Common Equity figures came in at $303.1 million (Q4 2025), $703.6 million (Q3 2025), and $706.7 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Keros Therapeutics | 217.21 Mn | -40.40 Mn | - | 262.32 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 262.32 Mn |
| Dec 31, 2025 | 303.13 Mn |
| Sep 30, 2025 | 703.58 Mn |
| Jun 30, 2025 | 706.73 Mn |
| Mar 31, 2025 | 728.87 Mn |
| Dec 31, 2024 | 571.55 Mn |
| Sep 30, 2024 | 532.84 Mn |
| Jun 30, 2024 | 420.92 Mn |
| Mar 31, 2024 | 453.95 Mn |
| Dec 31, 2023 | 332.21 Mn |
| Sep 30, 2023 | 295.84 Mn |
| Jun 30, 2023 | 326.26 Mn |
| Mar 31, 2023 | 354.98 Mn |
| Dec 31, 2022 | 277.42 Mn |
| Sep 30, 2022 | 241.03 Mn |
| Jun 30, 2022 | 211.21 Mn |
| Mar 31, 2022 | 223.49 Mn |
| Dec 31, 2021 | 243.17 Mn |
| Sep 30, 2021 | 218.48 Mn |
| Jun 30, 2021 | 235.66 Mn |